Non-internalising antibody–drug conjugates-Reference-Cited by-同舟云学术

Non-internalising antibody–drug conjugates

Published:2022 Issue:22 Volume:51 Page:9182-9202
ISSN:0306-0012
Container-title:Chemical Society Reviews
language:en
Short-container-title:Chem. Soc. Rev.

Author:

Ashman Nicola¹^ORCID,Bargh Jonathan D.²^ORCID,Spring David R.¹^ORCID

Affiliation:

1. Yusuf Hamied Department of Chemistry University of Cambridge Lensfield Road, Cambridge, CB2 1EW, UK

2. Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Abstract

This review introduces non-internalising Antibody–Drug Conjugates (ADCs), highlighting the linker chemistry that enables extracellular payload release.

Funder

Engineering and Physical Sciences Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/CS/D2CS00446A

Reference57 articles.

1. Targeting cancer with antibody-drug conjugates: Promises and challenges

2. Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

3. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy

4. Cleavable linkers in antibody–drug conjugates

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LC-MS/MS method for dual-ligand peptide-drug CBP-1018 and its deconjugated payload MMAE including sample stabilization strategy for its MC-Val-Cit-PABC linker;Talanta;2024-11

2. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?;Cancer Treatment Reviews;2024-09

3. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

4. Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs;World Journal of Oncology;2024-08

5. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28